Encorafenib
- TRADE NAME: Braftovi (Array Biopharma Inc)
- INDICATIONS: in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- CLASS: Kinase inhibitor
- HALF-LIFE: 3.5 hours
FDA APPROVAL DATE: 06/27/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
OTHER.
Page last updated 12/06/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric